长期使用钙调神经磷酸酶抑制剂的肾移植受者呈现双重免疫表型
该研究纳入114例肾移植受者,将38例移植后超过25年且移植物功能稳定、仍使用钙调神经磷酸酶抑制剂的患者,与移植后10-15年和5-7年的两组患者匹配比较。结果显示极长期患者的总B细胞比例显著降低、CD24HiCD38Lo记忆B细胞比例显著升高、CD24LoCD38Lo初始B细胞显著减少、PD1HiCCR7Lo Tfh淋巴细胞比例显著降低,且该表型与移植超过25年患者的耐受复合评分阳性相关,提示极长期肾移植患者存在与低排斥风险相关的双重表型。
要点
- 移植超过25年的患者总B细胞比例显著低于较近期移植患者
- 极长期患者记忆B细胞升高、初始B细胞和PD1HiCCR7Lo Tfh降低
- 该免疫表型与耐受复合评分阳性相关,提示低排斥风险
核心结论
- 极长期肾移植受者虽仍在钙调神经磷酸酶抑制剂治疗下,但呈现与低免疫排斥风险相关的免疫表型,提示双重表型。
研究设计与样本
- 研究纳入114例肾移植受者,其中38例移植超过25年且移植物功能稳定、使用钙调神经磷酸酶抑制剂,与移植后10-15年和5-7年的两组患者匹配比较。
主要发现
- 极长期患者总B细胞百分比显著低于较近期移植患者。
- 极长期患者CD24HiCD38Lo记忆B细胞比例显著升高。
- 极长期患者CD24LoCD38Lo初始B细胞显著减少。
- 极长期患者PD1HiCCR7Lo Tfh淋巴细胞比例显著降低。
- 移植超过25年的患者该表型与耐受复合评分阳性相关。
临床怎么用
- 对长期稳定且使用钙调神经磷酸酶抑制剂的肾移植受者,可关注B细胞亚群和Tfh表型以评估免疫状态。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Operationally tolerant kidney transplant recipients harbor an immunological signature, associated with low rejection risk, and focused on B lymphocytes. Here, we investigated whether patients with long-term transplantation and still on immunosuppressive therapy would present such a signature of low immunological rejection risk, compared to more recently transplanted patients. Of 114 kidney transplant recipients enrolled, 38 with more than 25 years of graft survival and stable graft function under calcineurin inhibitors, were matched with two different groups of transplanted patients (10-15 and 5-7 years after transplantation). Three phenotypes associated with low immunological rejection risk (Tfh, B and regulatory T cells), initially found in operationally tolerant kidney transplant recipients, and the composite score of tolerance (combination of six transcriptomic markers, age at transplantation and age at sampling) were analyzed. We found that very long-term patients were characterized by a significantly lower percentage of total B cells, a significantly higher proportion of CD24HiCD38Lo memory B cells, significantly fewer CD24LoCD38Lo naive B cells, and a significantly lower proportion of PD1HiCCR7Lo Tfh lymphocytes than more recently transplanted patients. This phenotype is associated with a positive composite score of tolerance in patients transplanted for more than 25 years. Thus, our study suggests a dual phenotype in very long-term kidney transplanted patients with an immunological profile associated with low rejection risk.
引用
- Dujardin A, Chesneau M, Dubois F, et al. Clinical and immunological follow-up of very long-term kidney transplant recipients treated with calcineurin inhibitors indicates dual phenotypes. Kidney Int. 2020. PMID: 33137335. doi:10.1016/j.kint.2020.09.036
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。